The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: FGF1 (Fibroblast Growth Factor 1)

Gene Identity Verification

The research target FGF1 (UniProt: P05230) corresponds to human fibroblast growth factor 1, also known as acidic fibroblast growth factor (aFGF), heparin-binding growth factor 1 (HBGF-1), or endothelial cell growth factor (ECGF) (edirisinghe2024decodingfgffgfrsignaling pages 3-4, tiwari2024fibroblastgrowthfactors pages 2-4, farooq2021theroleof pages 1-2). FGF1 belongs to the heparin-binding growth factors family and contains characteristic fibroblast growth factor (FGF) family domains consistent with the UniProt annotation provided (edirisinghe2024decodingfgffgfrsignaling pages 3-4, farooq2021theroleof pages 2-5). The gene symbol, organism, protein family, and functional domains all align with the protein description, confirming we are investigating the correct gene product.

Primary Molecular Function and Mechanism of Action

Receptor Specificity and Ligand-Receptor Interactions

FGF1 functions primarily as a signaling ligand for fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases (gasser2022metabolicmessengersfibroblast pages 9-11, edirisinghe2024decodingfgffgfrsignaling pages 3-4). Unlike many FGF family members with restricted receptor specificity, FGF1 exhibits remarkable promiscuity as a "universal ligand" capable of binding and activating all four principal FGFRs (FGFR1, FGFR2, FGFR3, and FGFR4), including their alternatively spliced IIIb and IIIc isoforms (edirisinghe2024decodingfgffgfrsignaling pages 3-4, farooq2021theroleof pages 2-5, tome2023fibroblastgrowthfactor pages 2-4). This broad receptor-binding capacity distinguishes FGF1 within the FGF family and underlies its ability to initiate diverse cellular responses across different tissue contexts (gasser2022metabolicmessengersfibroblast pages 9-11, edirisinghe2024decodingfgffgfrsignaling pages 4-5).

The ligand-receptor interaction occurs through binding of FGF1 to the extracellular D2-D3 immunoglobulin-like domains of FGFRs (edirisinghe2024decodingfgffgfrsignaling pages 3-4, edirisinghe2024decodingfgffgfrsignaling pages 4-5). Upon FGF1 binding, receptors undergo conformational changes that promote receptor dimerization, bringing together the intracellular tyrosine kinase domains (gasser2022metabolicmessengersfibroblast pages 9-11, chen2022rolesofthe pages 3-4). This proximity relieves autoinhibition and enables trans-autophosphorylation of tyrosine residues, including critical sites such as Tyr653 and Tyr654, which increases kinase activity and creates docking sites for downstream signaling effectors and adaptor proteins (chen2022rolesofthe pages 3-4, xie2020fgffgfrsignalingin pages 1-2).

Essential Role of Heparan Sulfate Proteoglycans

A defining feature of FGF1 signaling is its absolute requirement for heparan sulfate (HS) or heparin as a cofactor (ciura2025reprogrammingfgf1from pages 1-2, szybowska2021thecanonicalfgffgfr pages 2-4, tiwari2024fibroblastgrowthfactors pages 2-4). Heparan sulfate proteoglycans (HSPGs) function as low-affinity coreceptors that bind both FGF1 and FGFRs through sulfated domains interacting with positively charged residues (ciura2025reprogrammingfgf1from pages 1-2, chen2022rolesofthe pages 3-4). HS serves multiple critical functions: it stabilizes FGF1 against thermal denaturation, concentrates the growth factor near cell surfaces and in the extracellular matrix, restricts FGF1 diffusion to enable localized signaling, facilitates productive ligand-receptor assembly, and promotes or stabilizes FGFR dimerization (an2023heparinisessential pages 7-8, szybowska2021thecanonicalfgffgfr pages 2-4, tiwari2024fibroblastgrowthfactors pages 2-4, farooq2021theroleof pages 2-5).

The current evidence supports that HS/heparin enables formation of an FGF1-HS-FGFR signaling complex at the cell surface (szybowska2021thecanonicalfgffgfr pages 2-4, edirisinghe2024decodingfgffgfrsignaling pages 3-4). While both symmetric (1:1:1 FGF-FGFR-HS complex) and asymmetric models have been proposed, the ternary complex arrangement is essential for productive FGFR activation and downstream signaling (an2023heparinisessential pages 7-8, szybowska2021thecanonicalfgffgfr pages 2-4, xie2020fgffgfrsignalingin pages 1-2). Without HS/heparin, FGF1 cannot efficiently activate FGFRs even when the ligand and receptor are both present (an2023heparinisessential pages 7-8, chen2022rolesofthe pages 3-4).

Downstream Signaling Pathways

FGF1-mediated FGFR activation initiates four major intracellular signaling cascades that regulate diverse cellular processes (edirisinghe2024decodingfgffgfrsignaling pages 1-3, ferguson2021fibroblastgrowthfactor pages 3-5):

RAS-MAPK Pathway: Phosphorylated FGFRs recruit the adaptor protein FRS2α (fibroblast growth factor receptor substrate 2α), which serves as a central scaffolding hub (edirisinghe2024decodingfgffgfrsignaling pages 1-3, tome2023fibroblastgrowthfactor pages 2-4, klimaschewski2021fibroblastgrowthfactor pages 2-4). FRS2α recruits GRB2 (growth factor receptor-bound protein 2) and SOS (son of sevenless), activating the RAS-RAF-MEK-ERK cascade (edirisinghe2024decodingfgffgfrsignaling pages 1-3, liu2021fgfmechanismof pages 4-5, ferguson2021fibroblastgrowthfactor pages 3-5). This pathway drives proliferation, differentiation, migration, angiogenesis, and developmental transcription programs (edirisinghe2024decodingfgffgfrsignaling pages 1-3, tome2023fibroblastgrowthfactor pages 2-4). Recent studies reveal that prolonged MAPK/ERK activation in the hypothalamus mediates FGF1's antidiabetic effects (edirisinghe2024decodingfgffgfrsignaling pages 3-4).

PI3K-AKT Pathway: The FRS2α-GRB2 complex also recruits GAB1 (GRB2-associated binding protein 1) and activates phosphatidylinositol-3-kinase (PI3K), leading to AKT phosphorylation and downstream mTOR activation (edirisinghe2024decodingfgffgfrsignaling pages 1-3, liu2026fgffamilyin pages 3-4, ferguson2021fibroblastgrowthfactor pages 3-5). This pathway promotes cell survival by inhibiting pro-apoptotic factors such as caspase 9, BAD, and BAX (liu2026fgffamilyin pages 3-4). The PI3K-AKT pathway is particularly important for FGF1's metabolic effects, including suppression of adipose lipolysis through PDE4D activation, enhancement of skeletal muscle glucose uptake via AMPK-dependent GLUT4 translocation, and protection of diabetic cardiac tissue through restored mitochondrial function (gasser2022metabolicmessengersfibroblast pages 18-21, gasser2022metabolicmessengersfibroblast pages 4-6, gasser2022metabolicmessengersfibroblast pages 6-7).

PLCγ Pathway: FGFRs directly recruit and phosphorylate phospholipase C gamma (PLCγ), classically at FGFR Tyr766, activating its enzymatic activity (edirisinghe2024decodingfgffgfrsignaling pages 3-4, edirisinghe2024decodingfgffgfrsignaling pages 1-3, tome2023fibroblastgrowthfactor pages 2-4). Activated PLCγ hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (edirisinghe2024decodingfgffgfrsignaling pages 1-3, liu2026fgffamilyin pages 3-4). IP3 triggers calcium release from intracellular stores and activates NFAT (nuclear factor of activated T cells) nuclear translocation, while DAG activates protein kinase C (PKC) and MARCKS (liu2026fgffamilyin pages 3-4, tome2023fibroblastgrowthfactor pages 2-4). This pathway regulates calcium-dependent transcription, cytoskeletal remodeling, membrane dynamics, and cell migration (edirisinghe2024decodingfgffgfrsignaling pages 1-3, tome2023fibroblastgrowthfactor pages 2-4).

STAT Pathway: FGF1-activated FGFRs can phosphorylate STAT transcription factors (STAT1, STAT3, and STAT5), either directly or with participation of SRC family kinases or JAK kinases, depending on cellular context (edirisinghe2024decodingfgffgfrsignaling pages 1-3, ferguson2021fibroblastgrowthfactor pages 3-5, ferguson2021fibroblastgrowthfactor pages 2-3). Phosphorylated STATs dimerize and translocate to the nucleus to regulate transcription of genes involved in proliferation, differentiation, survival, and inflammatory responses (edirisinghe2024decodingfgffgfrsignaling pages 1-3, ferguson2021fibroblastgrowthfactor pages 5-7).

Table: This table maps FGF1 binding across FGFR1–4 and the essential heparan-sulfate coreceptor to the principal RAS–MAPK, PI3K–AKT, PLCγ and STAT signaling branches. It distinguishes receptor specificity, proximal effectors and major biological outcomes.

Subcellular Localization and Cellular Trafficking

Unconventional Secretion Mechanism

Unlike most secreted proteins, FGF1 lacks an N-terminal signal peptide for entry into the classical endoplasmic reticulum-Golgi secretory pathway (edirisinghe2024decodingfgffgfrsignaling pages 3-4, biadun2024uncoveringkeysteps pages 1-2, ferguson2021fibroblastgrowthfactor pages 25-26). Instead, FGF1 is exported through unconventional protein secretion (UPS), specifically a stress-responsive, non-classical route (edirisinghe2024decodingfgffgfrsignaling pages 3-4, biadun2024uncoveringkeysteps pages 9-11, prudovsky2021cellularmechanismsof pages 18-19). Cellular stresses including heat shock, serum deprivation, hypoxia, and elevated temperature trigger FGF1 release (biadun2024uncoveringkeysteps pages 9-11, prudovsky2021cellularmechanismsof pages 18-19, biadun2024uncoveringkeysteps pages 5-7).

The unconventional secretion mechanism involves formation of multiprotein complexes containing S100A13, the p40 form of synaptotagmin-1, and AHNAK2 (edirisinghe2024decodingfgffgfrsignaling pages 3-4, prudovsky2021cellularmechanismsof pages 18-19). Recent studies have identified additional critical components: the Na⁺/K⁺-ATPase A1 subunit (ATP1A1), Tec kinase, and specific phospholipids including phosphatidylserine and phosphatidylinositol (biadun2024uncoveringkeysteps pages 9-11, biadun2024uncoveringkeysteps pages 7-9, biadun2024uncoveringkeysteps pages 5-7). The process involves plasma membrane remodeling, phosphatidylserine externalization, and membrane blebbing (prudovsky2021cellularmechanismsof pages 18-19). Inhibition of Na⁺/K⁺-ATPase with ouabain or blockade of Tec kinase significantly reduces FGF1 secretion, confirming their essential roles in this pathway (biadun2024uncoveringkeysteps pages 9-11, biadun2024uncoveringkeysteps pages 7-9, biadun2024uncoveringkeysteps pages 5-7).

Extracellular Localization and Presentation

Once secreted, FGF1 is retained in the extracellular space and extracellular matrix through binding to heparan sulfate proteoglycans (ciura2025reprogrammingfgf1from pages 1-2, tiwari2024fibroblastgrowthfactors pages 2-4, farooq2021theroleof pages 2-5). This localization restricts FGF1 diffusion, creating high local concentrations near sites of secretion and enabling focused autocrine or paracrine signaling (tiwari2024fibroblastgrowthfactors pages 2-4, farooq2021theroleof pages 2-5). Cell-surface HSPGs present FGF1 to FGFRs, facilitating formation of the productive signaling complex (ciura2025reprogrammingfgf1from pages 1-2, an2023heparinisessential pages 7-8, edirisinghe2024decodingfgffgfrsignaling pages 3-4).

Intracellular Localization: Cytoplasmic and Nuclear Compartments

FGF1 exhibits complex intracellular trafficking patterns. After binding to FGFR1 or FGFR4 on the cell surface, FGF1 undergoes receptor-mediated endocytosis into early endosomes (lampart2022nuclearlocalizationsequence pages 1-2, lampart2022nuclearlocalizationsequence pages 2-3). From endosomes, FGF1 can translocate into the cytosol through a process requiring vesicular membrane potential and involving cytosolic factors including PI3K, HSP90, and p38 kinase (lampart2022nuclearlocalizationsequence pages 1-2, lampart2022nuclearlocalizationsequence pages 2-3). Importantly, this internalization and translocation occurs independently of FGFR tyrosine kinase activity, although the receptor's C-terminal sequence is required (lampart2022nuclearlocalizationsequence pages 1-2).

Once in the cytosol, wild-type FGF1 can undergo nuclear import mediated by two nuclear localization sequences (NLS): an N-terminal NLS (NYKKPKL, residues 21-27) and a bipartite NLS consisting of two lysine clusters (lampart2022nuclearlocalizationsequence pages 1-2, lampart2022nuclearlocalizationsequence pages 2-3). Nuclear translocation requires classical nuclear import machinery, including karyopherin alpha1, karyopherin beta1, exportin-1, Ran, and critically, LRRC59 (leucine-rich repeat-containing protein 59), which is essential for nuclear import of exogenous FGF1 (lampart2022nuclearlocalizationsequence pages 1-2, lampart2022nuclearlocalizationsequence pages 2-3). Nuclear accumulation peaks approximately six hours after FGFR binding (lampart2022nuclearlocalizationsequence pages 2-3). FGF1 is not permanently retained in the nucleus; PKCδ-mediated phosphorylation at serine 130 generates a nuclear export signal, and a leucine-rich nuclear export sequence (NES) mediates export back to the cytosol, followed by degradation (lampart2022nuclearlocalizationsequence pages 2-3).

Table: This table maps human FGF1 across extracellular, endosomal, cytoplasmic, and nuclear compartments, linking each location to its trafficking mechanism, molecular machinery, and experimentally supported functions.

Intracellular Functions: Anti-Apoptotic Activity

Beyond its canonical extracellular signaling role, FGF1 possesses important intracellular, or intracrine, functions that are independent of FGFR kinase activation (lampart2023intracellularfgf1protects pages 11-13, lampart2023intracellularfgf1protects pages 1-2, lampart2022nuclearlocalizationsequence pages 12-14). Recent research has revealed that intracellular FGF1 protects cells from apoptosis induced by diverse stresses, including staurosporine, anisomycin, actinomycin D, camptothecin, etoposide, and doxorubicin (lampart2023intracellularfgf1protects pages 1-2, lampart2023intracellularfgf1protects pages 5-7). This protective effect persists when FGFR signaling is pharmacologically blocked, confirming that it represents a receptor-independent survival mechanism (lampart2023intracellularfgf1protects pages 1-2, lampart2023intracellularfgf1protects pages 5-7, lampart2023intracellularfgf1protects pages 4-5).

Mechanism: Direct Interaction with p53

The anti-apoptotic activity of intracellular FGF1 is strictly dependent on the presence of functional wild-type p53 (lampart2023intracellularfgf1protects pages 1-2, lampart2023intracellularfgf1protects pages 7-9). FGF1 expression or translocation protects p53-positive cells but provides no protection in p53-null cells or cells with silenced p53 (lampart2023intracellularfgf1protects pages 1-2, lampart2023intracellularfgf1protects pages 7-9). Reintroduction of wild-type p53 into p53-negative cells restores FGF1's protective activity, demonstrating that p53 is required rather than merely associated (lampart2023intracellularfgf1protects pages 1-2).

Mechanistically, intracellular FGF1 directly binds p53 within cells, with the interaction involving the DNA-binding domain (DBD) of p53 (residues 94-312) (lampart2023intracellularfgf1protects pages 11-13, lampart2023intracellularfgf1protects pages 1-2). Surface plasmon resonance experiments demonstrated direct binding with dissociation constants of 5.59 × 10⁻⁷ M for full-length p53 and 4.37 × 10⁻⁷ M for the DNA-binding domain alone (lampart2023intracellularfgf1protects pages 11-13). The FGF1-p53 complex exhibits a broadly cytoplasmic distribution (lampart2023intracellularfgf1protects pages 11-13). This direct physical interaction suppresses p53-dependent intrinsic apoptosis, acting upstream of mitochondrial outer membrane permeabilization (MOMP), as evidenced by preserved mitochondrial membrane potential, reduced caspase-3/7 activity, and decreased PARP cleavage (lampart2023intracellularfgf1protects pages 1-2, lampart2022nuclearlocalizationsequence pages 12-14, lampart2023intracellularfgf1protects pages 5-7).

Importantly, recent studies demonstrate that nuclear localization is not required for FGF1's anti-apoptotic activity in differentiated cells (lampart2022nuclearlocalizationsequence pages 12-14, lampart2022nuclearlocalizationsequence pages 1-2). FGF1 variants with mutated or deleted nuclear localization sequences remain cytosolic yet retain substantial protective activity, indicating that the survival function can occur outside the nucleus (lampart2022nuclearlocalizationsequence pages 12-14, lampart2022nuclearlocalizationsequence pages 1-2). This finding suggests that the protective mechanism involves cytoplasmic FGF1-p53 interactions rather than nuclear transcriptional regulation.

Biological Processes and Biochemical Pathways

Cell Proliferation and Differentiation

FGF1 is a prototypical mitogenic factor that stimulates cell proliferation across multiple cell types, including preadipocytes, endothelial cells, epithelial cells, fibroblasts, and neural stem cells (edirisinghe2024decodingfgffgfrsignaling pages 3-4, tiwari2024fibroblastgrowthfactors pages 6-7, edirisinghe2024decodingfgffgfrsignaling pages 17-20). This mitogenic activity is mediated primarily through the RAS-MAPK pathway, which activates transcriptional programs driving cell-cycle progression (edirisinghe2024decodingfgffgfrsignaling pages 1-3, tome2023fibroblastgrowthfactor pages 2-4). FGF1 also regulates cellular differentiation, including neuroepithelial cell differentiation and adipocyte development (edirisinghe2024decodingfgffgfrsignaling pages 3-4, tiwari2024fibroblastgrowthfactors pages 6-7).

Angiogenesis and Vascular Development

FGF1 exhibits prominent angiogenic properties, promoting the proliferation and organization of endothelial cells into tubular structures characteristic of new blood vessels (edirisinghe2024decodingfgffgfrsignaling pages 3-4, tiwari2024fibroblastgrowthfactors pages 6-7, prudovsky2021cellularmechanismsof pages 5-6, edirisinghe2024decodingfgffgfrsignaling pages 17-20). This angiogenic activity is critical for embryonic vascular development, wound healing, and tissue repair, where new vessel formation supplies nutrients, oxygen, and immune cells to injured or regenerating tissues (prudovsky2021cellularmechanismsof pages 5-6, edirisinghe2024decodingfgffgfrsignaling pages 17-20, farooq2021theroleof pages 1-2). In the retina, FGF1 promotes retinal pigment epithelial cell survival through FGF1-FGFR1-ERK2 signaling and Bcl-x production (edirisinghe2024decodingfgffgfrsignaling pages 3-4).

Tissue Repair and Regeneration

FGF1 plays significant roles in tissue repair and wound healing across multiple organ systems (liu2026fgffamilyin pages 12-13, prudovsky2021cellularmechanismsof pages 5-6, farooq2021theroleof pages 7-9, liu2026fgffamilyin pages 13-15). Recombinant FGF1 accelerates healing of skin wounds, diabetic ulcers, spinal cord injuries, and bone fractures (farooq2021theroleof pages 7-9). In the context of tissue injury, FGF1 expression and secretion increase in response to damage, initiating coordinated cellular responses including inflammation control, extracellular matrix remodeling, and tissue regeneration (liu2026fgffamilyin pages 12-13, liu2026fgffamilyin pages 13-15).

FGF1 regulates matrix metalloproteinases (MMP1, MMP3, MMP9) in endothelial and epithelial cells, supporting extracellular matrix remodeling necessary for repair (prudovsky2021cellularmechanismsof pages 5-6). During acute inflammation, FGF1 reduces tissue damage, edema, and inflammatory cell infiltration by suppressing TLR4-NF-κB signaling and strengthening Nrf2-dependent antioxidant defenses (liu2026fgffamilyin pages 12-13, liu2026fgffamilyin pages 13-15). These anti-inflammatory and antioxidant effects limit apoptosis and protect injured tissue (liu2026fgffamilyin pages 12-13, liu2026fgffamilyin pages 13-15).

Metabolic Regulation and Glucose Homeostasis

Recent research has revealed important metabolic functions for FGF1, particularly in glucose regulation and diabetes (gasser2022metabolicmessengersfibroblast pages 18-21, gasser2022metabolicmessengersfibroblast pages 11-12, gasser2022metabolicmessengersfibroblast pages 7-9, gasser2022metabolicmessengersfibroblast pages 1-3, gasser2022metabolicmessengersfibroblast pages 4-6). This represents a major expansion of FGF1's recognized biological roles and has generated substantial interest in its therapeutic potential.

Adipose Tissue Actions: In adipose tissue, endogenous FGF1 production rises during dietary stress, particularly under high-fat diet conditions, and is required for appropriate white adipose tissue remodeling and vascularization (gasser2022metabolicmessengersfibroblast pages 1-3, gasser2022metabolicmessengersfibroblast pages 4-6). FGF1 acts through FGFR1 and PI3K signaling to activate phosphodiesterase 4D (PDE4D), which reduces cyclic AMP (cAMP) and PKA-dependent phosphorylation of hormone-sensitive lipase and perilipin, thereby suppressing lipolysis (gasser2022metabolicmessengersfibroblast pages 18-21, gasser2022metabolicmessengersfibroblast pages 4-6, gasser2022metabolicmessengersfibroblast pages 6-7). This anti-lipolytic action decreases free fatty acid release to the liver, limiting fatty acid-driven hepatic gluconeogenesis and contributing to blood glucose lowering (gasser2022metabolicmessengersfibroblast pages 18-21, gasser2022metabolicmessengersfibroblast pages 6-7).

FGF1 also promotes adipocyte hyperplasia (increased adipocyte number) rather than hypertrophy (increased adipocyte size) in response to nutrient or mechanical stress, a pattern associated with healthier metabolic outcomes (gasser2022metabolicmessengersfibroblast pages 18-21, gasser2022metabolicmessengersfibroblast pages 1-3). Loss of FGF1 or its mechanosensor Piezo1 worsens diet-induced insulin resistance (gasser2022metabolicmessengersfibroblast pages 18-21).

Skeletal Muscle Glucose Uptake: In skeletal muscle, FGF1 activates AMP-activated protein kinase (AMPK) and increases both expression and plasma membrane translocation of the glucose transporter GLUT4, promoting glucose uptake (gasser2022metabolicmessengersfibroblast pages 18-21, gasser2022metabolicmessengersfibroblast pages 4-6, gasser2022metabolicmessengersfibroblast pages 6-7). Disruption of muscle FGFR1 or AMPKα2 attenuates these effects (gasser2022metabolicmessengersfibroblast pages 6-7).

Central Nervous System Effects: When administered centrally by intracerebroventricular injection or directly into the hypothalamic arcuate nucleus, FGF1 produces remarkably sustained glucose-lowering effects in multiple diabetic animal models, including ob/ob, db/db, and diet-induced diabetes (gasser2022metabolicmessengersfibroblast pages 7-9, gasser2022metabolicmessengersfibroblast pages 1-3, gasser2022metabolicmessengersfibroblast pages 6-7). A single central injection can restore normoglycemia for periods as long as 18 weeks without causing hypoglycemia (gasser2022metabolicmessengersfibroblast pages 7-9, gasser2022metabolicmessengersfibroblast pages 6-7). These effects involve hypothalamic glucoregulatory circuits, AGRP neurons, astrocytic interactions, melanocortin receptor 4 signaling, and remodeling of the perineuronal net (gasser2022metabolicmessengersfibroblast pages 7-9). Prolonged MAPK/ERK activation in the hypothalamus has been identified as a key mechanism (edirisinghe2024decodingfgffgfrsignaling pages 3-4).

Therapeutic Implications: Peripheral FGF1 administration rapidly restores normoglycemia in obese diabetic mice and maintains glucose control with repeated dosing, without causing hypoglycemia (gasser2022metabolicmessengersfibroblast pages 11-12, gasser2022metabolicmessengersfibroblast pages 4-6). Chronic treatment improves insulin sensitivity independently of weight loss, increases hepatic glycogen, and reduces hepatic steatosis and inflammation (gasser2022metabolicmessengersfibroblast pages 4-6). FGF1 also reverses fatty liver through FGFR4-AMPKα signaling, reduces oxidative stress through Nrf2 and antioxidant proteins, and protects diabetic cardiac tissue by restoring mitochondrial function (liu2026fgffamilyin pages 12-13, gasser2022metabolicmessengersfibroblast pages 4-6).

Recent Developments and Current Research (2023-2026)

Engineered FGF1 Variants for Diabetes Therapy

A major focus of recent research has been engineering FGF1 variants that preserve glucose-lowering activity while reducing unwanted mitogenic effects (gasser2022metabolicmessengersfibroblast pages 11-12). FGF1's ability to activate multiple FGFRs and stimulate proliferation raises concerns about tumor promotion and other proliferative side effects. Recent studies have successfully developed FGF1 variants with reduced mitogenicity but retained metabolic benefits through rational mutations that modulate receptor binding, heparan sulfate interactions, and thermodynamic stability (gasser2022metabolicmessengersfibroblast pages 11-12).

A 2026 study reported engineered FGF1 variants that fully maintained potent glucose-lowering properties in db/db diabetic mice without inducing hypoglycemia or body weight changes, while exhibiting significantly reduced mitogenic potential across various cell types (Czyrek et al., 2026, Molecular Biomedicine). These variants demonstrated superior thermodynamic stability and markedly improved pharmacokinetic profiles, critical attributes for drug development. The strategy successfully uncoupled FGF1's therapeutic metabolic benefits from its proliferative side effects, offering promising protein-based drug candidates for type 2 diabetes treatment.

FGF1 in Diabetic Complications

Recent research has expanded understanding of FGF1's protective effects in diabetic complications beyond glucose control. A 2026 study demonstrated that FGF1 treatment alleviates diabetic nephropathy by reducing renal lipid accumulation (Li et al., 2026, World Journal of Diabetes). FGF1 normalized expression of CD36 (a fatty acid uptake regulator) and carnitine palmitoyltransferase 1A (a rate-limiting enzyme in fatty acid β-oxidation), enhanced fatty acid oxidation in kidney cells, and restored AMPK activity and PPARα expression. Pharmacological inhibition of AMPK or fatty acid oxidation abolished FGF1's protective effects, confirming the mechanistic pathway.

FGF1 has also shown promise in wound healing applications. A 2024 study found that combined VEGF-A and FGF1 modified mRNA, delivered in lipid nanoparticles, improved wound healing in diabetic mice by promoting faster wound closure and increased neovascularization (Tejedor et al., 2024, Cells).

Intracellular Mechanisms and p53 Interaction

The discovery and characterization of FGF1's intracellular anti-apoptotic function through direct p53 interaction represents a major recent advance (Lampart et al., 2023, Cellular and Molecular Life Sciences). This work established that intracellular FGF1 protects cells from apoptosis in a strictly p53-dependent manner, acts upstream of mitochondrial outer membrane permeabilization, and functions through direct physical binding to p53's DNA-binding domain. These findings reveal a previously unrecognized dimension of FGF1 biology that operates independently of classical FGFR signaling.

Unconventional Secretion Mechanisms

Recent studies have made significant progress in elucidating the molecular machinery underlying FGF1's unconventional secretion. A 2024 study identified key steps in the cellular release pathway, including critical roles for the Na⁺/K⁺-ATPase A1 subunit, Tec kinase, and specific lipids including phosphatidylserine (Biadun et al., 2024, Cellular and Molecular Life Sciences). This work suggested a common mechanism for unconventional secretion of multiple FGF family members that lack signal peptides, providing mechanistic insights that could enable therapeutic manipulation of FGF1 release.

Applications in Tissue-Specific Pathologies

Recent research has documented FGF1's roles in diverse tissue-specific contexts:

• Endometrial Repair: FGF1 ameliorates thin endometrium through activation of autophagic pathways involving p38, PI3K, SQSTM1/p62, beclin-1, and LC3 (Zhu et al., 2023, Frontiers in Pharmacology).

• Inflammatory Diseases: FGF1 reduces inflammation and oxidative stress in acute lung injury by downregulating TLR4 expression, inhibiting NF-κB activation, and promoting Nrf2-dependent antioxidant defenses (Dhlamini et al., 2022, Molecular Medicine).

• Cancer Biology: Studies have characterized FGF1-FGFR signaling in prostate cancer glycolysis and glioblastoma, revealing context-dependent roles in tumor metabolism and survival (Ye et al., 2024, Journal of Translational Medicine; Zhao et al., 2024, Oncology Letters).

Summary

FGF1 is a multifunctional signaling protein that operates through both extracellular receptor-mediated and intracellular receptor-independent mechanisms. As an extracellular ligand, FGF1 exhibits unique promiscuity in binding all four FGFRs (FGFR1-4) and their splice isoforms in a heparan sulfate-dependent manner, activating RAS-MAPK, PI3K-AKT, PLCγ, and STAT signaling pathways to regulate proliferation, differentiation, angiogenesis, tissue repair, and metabolic homeostasis. FGF1 lacks a signal peptide and is released through stress-responsive unconventional secretion involving Na⁺/K⁺-ATPase, Tec kinase, and accessory proteins.

Intracellularly, FGF1 localizes to the cytoplasm and nucleus through receptor-mediated endocytosis and LRRC59-dependent nuclear import, where it provides FGFR-independent anti-apoptotic activity through direct binding to p53's DNA-binding domain. Recent research has highlighted FGF1's potent metabolic effects, including suppression of adipose lipolysis, enhancement of muscle glucose uptake, and sustained central glucose-lowering effects in diabetic animal models without hypoglycemia. Engineered FGF1 variants with reduced mitogenicity but preserved metabolic activity represent promising therapeutic candidates for type 2 diabetes. The protein's diverse biological activities position it as a critical regulator of tissue homeostasis, injury responses, and metabolic regulation, with expanding therapeutic potential across multiple disease contexts.

References

1. (edirisinghe2024decodingfgffgfrsignaling pages 3-4): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

2. (tiwari2024fibroblastgrowthfactors pages 2-4): N Tiwari, A Tiwari, L Mehra, and A Ganguly. Fibroblast growth factors: properties, biosynthesis, biological functions, therapeutic applications and engineering. International Journal of Medical Biochemistry, pages 114-126, Jan 2024. URL: https://doi.org/10.14744/ijmb.2024.16768, doi:10.14744/ijmb.2024.16768. This article has 7 citations.

3. (farooq2021theroleof pages 1-2): Mariya Farooq, Abdul Waheed Khan, Moon Suk Kim, and Sangdun Choi. The role of fibroblast growth factor (fgf) signaling in tissue repair and regeneration. Cells, 10:3242, Nov 2021. URL: https://doi.org/10.3390/cells10113242, doi:10.3390/cells10113242. This article has 446 citations.

4. (farooq2021theroleof pages 2-5): Mariya Farooq, Abdul Waheed Khan, Moon Suk Kim, and Sangdun Choi. The role of fibroblast growth factor (fgf) signaling in tissue repair and regeneration. Cells, 10:3242, Nov 2021. URL: https://doi.org/10.3390/cells10113242, doi:10.3390/cells10113242. This article has 446 citations.

5. (gasser2022metabolicmessengersfibroblast pages 9-11): Emanuel Gasser, Gencer Sancar, Michael Downes, and Ronald M. Evans. Metabolic messengers: fibroblast growth factor 1. Jun 2022. URL: https://doi.org/10.1038/s42255-022-00580-2, doi:10.1038/s42255-022-00580-2. This article has 47 citations and is from a domain leading peer-reviewed journal.

6. (tome2023fibroblastgrowthfactor pages 2-4): Diogo Tomé, Marta S. Dias, Joana Correia, and Ramiro D. Almeida. Fibroblast growth factor signaling in axons: from development to disease. Cell Communication and Signaling : CCS, Oct 2023. URL: https://doi.org/10.1186/s12964-023-01284-0, doi:10.1186/s12964-023-01284-0. This article has 45 citations.

7. (edirisinghe2024decodingfgffgfrsignaling pages 4-5): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

8. (chen2022rolesofthe pages 3-4): Keyang Chen, Zhiheng Rao, Siyang Dong, Yajing Chen, Xulan Wang, Yongde Luo, Fanghua Gong, and Xiaokun Li. Roles of the fibroblast growth factor signal transduction system in tissue injury repair. Burns & Trauma, Mar 2022. URL: https://doi.org/10.1093/burnst/tkac005, doi:10.1093/burnst/tkac005. This article has 57 citations and is from a peer-reviewed journal.

9. (xie2020fgffgfrsignalingin pages 1-2): Yangli Xie, N. Su, Jing Yang, Q. Tan, Shuo Huang, M. Jin, Z. Ni, Bin Zhang, Dali Zhang, F. Luo, Hangang Chen, Xianding Sun, Jian Q. Feng, H. Qi, and Lin Chen. Fgf/fgfr signaling in health and disease. Signal Transduction and Targeted Therapy, Sep 2020. URL: https://doi.org/10.1038/s41392-020-00222-7, doi:10.1038/s41392-020-00222-7. This article has 1148 citations and is from a peer-reviewed journal.

10. (ciura2025reprogrammingfgf1from pages 1-2): Krzysztof Ciura, Olimpia Sobota, Aleksandra Chorążewska, Daniel Krowarsch, Natalia Porębska, and Łukasz Opaliński. Reprogramming fgf1 from the natural growth factor to the engineered heparan sulphate biosensor. Cell Communication and Signaling : CCS, May 2025. URL: https://doi.org/10.1186/s12964-025-02269-x, doi:10.1186/s12964-025-02269-x. This article has 0 citations.

11. (szybowska2021thecanonicalfgffgfr pages 2-4): Patrycja Szybowska, Ellen Margrethe Haugsten, and Antoni Wiedlocha. The canonical fgf-fgfr signaling system at the molecular level. Postępy Higieny i Medycyny Doświadczalnej, 75:711-719, Jan 2021. URL: https://doi.org/10.2478/ahem-2021-0024, doi:10.2478/ahem-2021-0024. This article has 1 citations.

12. (an2023heparinisessential pages 7-8): Seong J. An, Jyotidarsini Mohanty, Francisco Tome, Yoshihisa Suzuki, Irit Lax, and Joseph Schlessinger. Heparin is essential for optimal cell signaling by fgf21 and for regulation of βklotho cellular stability. Proceedings of the National Academy of Sciences of the United States of America, Feb 2023. URL: https://doi.org/10.1073/pnas.2219128120, doi:10.1073/pnas.2219128120. This article has 24 citations and is from a highest quality peer-reviewed journal.

13. (edirisinghe2024decodingfgffgfrsignaling pages 1-3): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

14. (ferguson2021fibroblastgrowthfactor pages 3-5): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

15. (klimaschewski2021fibroblastgrowthfactor pages 2-4): Lars Klimaschewski and Peter Claus. Fibroblast growth factor signalling in the diseased nervous system. Molecular Neurobiology, 58:3884-3902, Apr 2021. URL: https://doi.org/10.1007/s12035-021-02367-0, doi:10.1007/s12035-021-02367-0. This article has 152 citations and is from a peer-reviewed journal.

16. (liu2021fgfmechanismof pages 4-5): Yiqiu Liu, Junyu Deng, Ye Liu, Wei Li, and Xuqiang Nie. Fgf, mechanism of action, role in parkinson’s disease, and therapeutics. Frontiers in Pharmacology, Jun 2021. URL: https://doi.org/10.3389/fphar.2021.675725, doi:10.3389/fphar.2021.675725. This article has 62 citations.

17. (liu2026fgffamilyin pages 3-4): Xiaoyu Liu, Meiling Jing, Yueyi Yang, Qiaoqiao Jin, B. Feng, Pengfei Zhang, Chenguang Niu, Xuchen Hu, and Zheng-Wei Huang. Fgf family in health and disease. Molecular Biomedicine, Mar 2026. URL: https://doi.org/10.1186/s43556-026-00429-0, doi:10.1186/s43556-026-00429-0. This article has 10 citations and is from a peer-reviewed journal.

18. (gasser2022metabolicmessengersfibroblast pages 18-21): Emanuel Gasser, Gencer Sancar, Michael Downes, and Ronald M. Evans. Metabolic messengers: fibroblast growth factor 1. Jun 2022. URL: https://doi.org/10.1038/s42255-022-00580-2, doi:10.1038/s42255-022-00580-2. This article has 47 citations and is from a domain leading peer-reviewed journal.

19. (gasser2022metabolicmessengersfibroblast pages 4-6): Emanuel Gasser, Gencer Sancar, Michael Downes, and Ronald M. Evans. Metabolic messengers: fibroblast growth factor 1. Jun 2022. URL: https://doi.org/10.1038/s42255-022-00580-2, doi:10.1038/s42255-022-00580-2. This article has 47 citations and is from a domain leading peer-reviewed journal.

20. (gasser2022metabolicmessengersfibroblast pages 6-7): Emanuel Gasser, Gencer Sancar, Michael Downes, and Ronald M. Evans. Metabolic messengers: fibroblast growth factor 1. Jun 2022. URL: https://doi.org/10.1038/s42255-022-00580-2, doi:10.1038/s42255-022-00580-2. This article has 47 citations and is from a domain leading peer-reviewed journal.

21. (ferguson2021fibroblastgrowthfactor pages 2-3): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

22. (ferguson2021fibroblastgrowthfactor pages 5-7): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

23. (lampart2022nuclearlocalizationsequence pages 1-2): Agata Lampart, Katarzyna Dominika Sluzalska, Aleksandra Czyrek, Aleksandra Szerszen, Jacek Otlewski, Antoni Wiedlocha, and Malgorzata Zakrzewska. Nuclear localization sequence of fgf1 is not required for its intracellular anti-apoptotic activity in differentiated cells. Cells, 11:522, Feb 2022. URL: https://doi.org/10.3390/cells11030522, doi:10.3390/cells11030522. This article has 7 citations.

24. (biadun2024uncoveringkeysteps pages 1-2): Martyna Biadun, Martyna Sochacka, Marta Kalka, Aleksandra Chorazewska, Radoslaw Karelus, Daniel Krowarsch, Lukasz Opalinski, and Malgorzata Zakrzewska. Uncovering key steps in fgf12 cellular release reveals a common mechanism for unconventional fgf protein secretion. Cellular and Molecular Life Sciences: CMLS, Aug 2024. URL: https://doi.org/10.1007/s00018-024-05396-9, doi:10.1007/s00018-024-05396-9. This article has 12 citations.

25. (ferguson2021fibroblastgrowthfactor pages 25-26): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.

26. (biadun2024uncoveringkeysteps pages 9-11): Martyna Biadun, Martyna Sochacka, Marta Kalka, Aleksandra Chorazewska, Radoslaw Karelus, Daniel Krowarsch, Lukasz Opalinski, and Malgorzata Zakrzewska. Uncovering key steps in fgf12 cellular release reveals a common mechanism for unconventional fgf protein secretion. Cellular and Molecular Life Sciences: CMLS, Aug 2024. URL: https://doi.org/10.1007/s00018-024-05396-9, doi:10.1007/s00018-024-05396-9. This article has 12 citations.

27. (prudovsky2021cellularmechanismsof pages 18-19): Igor Prudovsky. Cellular mechanisms of fgf-stimulated tissue repair. Cells, 10:1830, Jul 2021. URL: https://doi.org/10.3390/cells10071830, doi:10.3390/cells10071830. This article has 93 citations.

28. (biadun2024uncoveringkeysteps pages 5-7): Martyna Biadun, Martyna Sochacka, Marta Kalka, Aleksandra Chorazewska, Radoslaw Karelus, Daniel Krowarsch, Lukasz Opalinski, and Malgorzata Zakrzewska. Uncovering key steps in fgf12 cellular release reveals a common mechanism for unconventional fgf protein secretion. Cellular and Molecular Life Sciences: CMLS, Aug 2024. URL: https://doi.org/10.1007/s00018-024-05396-9, doi:10.1007/s00018-024-05396-9. This article has 12 citations.

29. (biadun2024uncoveringkeysteps pages 7-9): Martyna Biadun, Martyna Sochacka, Marta Kalka, Aleksandra Chorazewska, Radoslaw Karelus, Daniel Krowarsch, Lukasz Opalinski, and Malgorzata Zakrzewska. Uncovering key steps in fgf12 cellular release reveals a common mechanism for unconventional fgf protein secretion. Cellular and Molecular Life Sciences: CMLS, Aug 2024. URL: https://doi.org/10.1007/s00018-024-05396-9, doi:10.1007/s00018-024-05396-9. This article has 12 citations.

30. (lampart2022nuclearlocalizationsequence pages 2-3): Agata Lampart, Katarzyna Dominika Sluzalska, Aleksandra Czyrek, Aleksandra Szerszen, Jacek Otlewski, Antoni Wiedlocha, and Malgorzata Zakrzewska. Nuclear localization sequence of fgf1 is not required for its intracellular anti-apoptotic activity in differentiated cells. Cells, 11:522, Feb 2022. URL: https://doi.org/10.3390/cells11030522, doi:10.3390/cells11030522. This article has 7 citations.

31. (lampart2022nuclearlocalizationsequence pages 12-14): Agata Lampart, Katarzyna Dominika Sluzalska, Aleksandra Czyrek, Aleksandra Szerszen, Jacek Otlewski, Antoni Wiedlocha, and Malgorzata Zakrzewska. Nuclear localization sequence of fgf1 is not required for its intracellular anti-apoptotic activity in differentiated cells. Cells, 11:522, Feb 2022. URL: https://doi.org/10.3390/cells11030522, doi:10.3390/cells11030522. This article has 7 citations.

32. (lampart2022nuclearlocalizationsequence pages 5-6): Agata Lampart, Katarzyna Dominika Sluzalska, Aleksandra Czyrek, Aleksandra Szerszen, Jacek Otlewski, Antoni Wiedlocha, and Malgorzata Zakrzewska. Nuclear localization sequence of fgf1 is not required for its intracellular anti-apoptotic activity in differentiated cells. Cells, 11:522, Feb 2022. URL: https://doi.org/10.3390/cells11030522, doi:10.3390/cells11030522. This article has 7 citations.

33. (lampart2023intracellularfgf1protects pages 11-13): Agata Lampart, Daniel Krowarsch, Martyna Biadun, Vigdis Sorensen, Jakub Szymczyk, Katarzyna Sluzalska, Antoni Wiedlocha, Jacek Otlewski, and Malgorzata Zakrzewska. Intracellular fgf1 protects cells from apoptosis through direct interaction with p53. Cellular and Molecular Life Sciences: CMLS, Oct 2023. URL: https://doi.org/10.1007/s00018-023-04964-9, doi:10.1007/s00018-023-04964-9. This article has 5 citations.

34. (lampart2023intracellularfgf1protects pages 1-2): Agata Lampart, Daniel Krowarsch, Martyna Biadun, Vigdis Sorensen, Jakub Szymczyk, Katarzyna Sluzalska, Antoni Wiedlocha, Jacek Otlewski, and Malgorzata Zakrzewska. Intracellular fgf1 protects cells from apoptosis through direct interaction with p53. Cellular and Molecular Life Sciences: CMLS, Oct 2023. URL: https://doi.org/10.1007/s00018-023-04964-9, doi:10.1007/s00018-023-04964-9. This article has 5 citations.

35. (lampart2023intracellularfgf1protects pages 5-7): Agata Lampart, Daniel Krowarsch, Martyna Biadun, Vigdis Sorensen, Jakub Szymczyk, Katarzyna Sluzalska, Antoni Wiedlocha, Jacek Otlewski, and Malgorzata Zakrzewska. Intracellular fgf1 protects cells from apoptosis through direct interaction with p53. Cellular and Molecular Life Sciences: CMLS, Oct 2023. URL: https://doi.org/10.1007/s00018-023-04964-9, doi:10.1007/s00018-023-04964-9. This article has 5 citations.

36. (lampart2023intracellularfgf1protects pages 7-9): Agata Lampart, Daniel Krowarsch, Martyna Biadun, Vigdis Sorensen, Jakub Szymczyk, Katarzyna Sluzalska, Antoni Wiedlocha, Jacek Otlewski, and Malgorzata Zakrzewska. Intracellular fgf1 protects cells from apoptosis through direct interaction with p53. Cellular and Molecular Life Sciences: CMLS, Oct 2023. URL: https://doi.org/10.1007/s00018-023-04964-9, doi:10.1007/s00018-023-04964-9. This article has 5 citations.

37. (lampart2023intracellularfgf1protects pages 4-5): Agata Lampart, Daniel Krowarsch, Martyna Biadun, Vigdis Sorensen, Jakub Szymczyk, Katarzyna Sluzalska, Antoni Wiedlocha, Jacek Otlewski, and Malgorzata Zakrzewska. Intracellular fgf1 protects cells from apoptosis through direct interaction with p53. Cellular and Molecular Life Sciences: CMLS, Oct 2023. URL: https://doi.org/10.1007/s00018-023-04964-9, doi:10.1007/s00018-023-04964-9. This article has 5 citations.

38. (tiwari2024fibroblastgrowthfactors pages 6-7): N Tiwari, A Tiwari, L Mehra, and A Ganguly. Fibroblast growth factors: properties, biosynthesis, biological functions, therapeutic applications and engineering. International Journal of Medical Biochemistry, pages 114-126, Jan 2024. URL: https://doi.org/10.14744/ijmb.2024.16768, doi:10.14744/ijmb.2024.16768. This article has 7 citations.

39. (edirisinghe2024decodingfgffgfrsignaling pages 17-20): Oshadi Edirisinghe, Gaëtane Ternier, Zeina Alraawi, and Thallapuranam Krishnaswamy Suresh Kumar. Decoding fgf/fgfr signaling: insights into biological functions and disease relevance. Biomolecules, 14:1622, Dec 2024. URL: https://doi.org/10.3390/biom14121622, doi:10.3390/biom14121622. This article has 67 citations.

40. (prudovsky2021cellularmechanismsof pages 5-6): Igor Prudovsky. Cellular mechanisms of fgf-stimulated tissue repair. Cells, 10:1830, Jul 2021. URL: https://doi.org/10.3390/cells10071830, doi:10.3390/cells10071830. This article has 93 citations.

41. (liu2026fgffamilyin pages 12-13): Xiaoyu Liu, Meiling Jing, Yueyi Yang, Qiaoqiao Jin, B. Feng, Pengfei Zhang, Chenguang Niu, Xuchen Hu, and Zheng-Wei Huang. Fgf family in health and disease. Molecular Biomedicine, Mar 2026. URL: https://doi.org/10.1186/s43556-026-00429-0, doi:10.1186/s43556-026-00429-0. This article has 10 citations and is from a peer-reviewed journal.

42. (farooq2021theroleof pages 7-9): Mariya Farooq, Abdul Waheed Khan, Moon Suk Kim, and Sangdun Choi. The role of fibroblast growth factor (fgf) signaling in tissue repair and regeneration. Cells, 10:3242, Nov 2021. URL: https://doi.org/10.3390/cells10113242, doi:10.3390/cells10113242. This article has 446 citations.

43. (liu2026fgffamilyin pages 13-15): Xiaoyu Liu, Meiling Jing, Yueyi Yang, Qiaoqiao Jin, B. Feng, Pengfei Zhang, Chenguang Niu, Xuchen Hu, and Zheng-Wei Huang. Fgf family in health and disease. Molecular Biomedicine, Mar 2026. URL: https://doi.org/10.1186/s43556-026-00429-0, doi:10.1186/s43556-026-00429-0. This article has 10 citations and is from a peer-reviewed journal.

44. (gasser2022metabolicmessengersfibroblast pages 11-12): Emanuel Gasser, Gencer Sancar, Michael Downes, and Ronald M. Evans. Metabolic messengers: fibroblast growth factor 1. Jun 2022. URL: https://doi.org/10.1038/s42255-022-00580-2, doi:10.1038/s42255-022-00580-2. This article has 47 citations and is from a domain leading peer-reviewed journal.

45. (gasser2022metabolicmessengersfibroblast pages 7-9): Emanuel Gasser, Gencer Sancar, Michael Downes, and Ronald M. Evans. Metabolic messengers: fibroblast growth factor 1. Jun 2022. URL: https://doi.org/10.1038/s42255-022-00580-2, doi:10.1038/s42255-022-00580-2. This article has 47 citations and is from a domain leading peer-reviewed journal.

46. (gasser2022metabolicmessengersfibroblast pages 1-3): Emanuel Gasser, Gencer Sancar, Michael Downes, and Ronald M. Evans. Metabolic messengers: fibroblast growth factor 1. Jun 2022. URL: https://doi.org/10.1038/s42255-022-00580-2, doi:10.1038/s42255-022-00580-2. This article has 47 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01

Citations

1. edirisinghe2024decodingfgffgfrsignaling pages 3-4
2. liu2026fgffamilyin pages 3-4
3. prudovsky2021cellularmechanismsof pages 18-19
4. lampart2022nuclearlocalizationsequence pages 1-2
5. lampart2022nuclearlocalizationsequence pages 2-3
6. farooq2021theroleof pages 7-9
7. prudovsky2021cellularmechanismsof pages 5-6
8. gasser2022metabolicmessengersfibroblast pages 18-21
9. gasser2022metabolicmessengersfibroblast pages 6-7
10. gasser2022metabolicmessengersfibroblast pages 7-9
11. gasser2022metabolicmessengersfibroblast pages 4-6
12. gasser2022metabolicmessengersfibroblast pages 11-12
13. tiwari2024fibroblastgrowthfactors pages 2-4
14. farooq2021theroleof pages 1-2
15. farooq2021theroleof pages 2-5
16. gasser2022metabolicmessengersfibroblast pages 9-11
17. tome2023fibroblastgrowthfactor pages 2-4
18. edirisinghe2024decodingfgffgfrsignaling pages 4-5
19. chen2022rolesofthe pages 3-4
20. xie2020fgffgfrsignalingin pages 1-2
21. szybowska2021thecanonicalfgffgfr pages 2-4
22. an2023heparinisessential pages 7-8
23. edirisinghe2024decodingfgffgfrsignaling pages 1-3
24. ferguson2021fibroblastgrowthfactor pages 3-5
25. klimaschewski2021fibroblastgrowthfactor pages 2-4
26. liu2021fgfmechanismof pages 4-5
27. ferguson2021fibroblastgrowthfactor pages 2-3
28. ferguson2021fibroblastgrowthfactor pages 5-7
29. biadun2024uncoveringkeysteps pages 1-2
30. ferguson2021fibroblastgrowthfactor pages 25-26
31. biadun2024uncoveringkeysteps pages 9-11
32. biadun2024uncoveringkeysteps pages 5-7
33. biadun2024uncoveringkeysteps pages 7-9
34. lampart2022nuclearlocalizationsequence pages 12-14
35. lampart2022nuclearlocalizationsequence pages 5-6
36. tiwari2024fibroblastgrowthfactors pages 6-7
37. edirisinghe2024decodingfgffgfrsignaling pages 17-20
38. liu2026fgffamilyin pages 12-13
39. liu2026fgffamilyin pages 13-15
40. gasser2022metabolicmessengersfibroblast pages 1-3
41. https://doi.org/10.3390/biom14121622,
42. https://doi.org/10.14744/ijmb.2024.16768,
43. https://doi.org/10.3390/cells10113242,
44. https://doi.org/10.1038/s42255-022-00580-2,
45. https://doi.org/10.1186/s12964-023-01284-0,
46. https://doi.org/10.1093/burnst/tkac005,
47. https://doi.org/10.1038/s41392-020-00222-7,
48. https://doi.org/10.1186/s12964-025-02269-x,
49. https://doi.org/10.2478/ahem-2021-0024,
50. https://doi.org/10.1073/pnas.2219128120,
51. https://doi.org/10.3390/cells10051201,
52. https://doi.org/10.1007/s12035-021-02367-0,
53. https://doi.org/10.3389/fphar.2021.675725,
54. https://doi.org/10.1186/s43556-026-00429-0,
55. https://doi.org/10.3390/cells11030522,
56. https://doi.org/10.1007/s00018-024-05396-9,
57. https://doi.org/10.3390/cells10071830,
58. https://doi.org/10.1007/s00018-023-04964-9,